24/7
Buzz
Startups
VC
@work
Innovation
Opinions
Events
Promising Startups 2022
BiblioTech
Boarding Pass
Appointments
CTalk
Tech Gateways
2022 VC Survey
@Finance
Ctech Testimonials
DataTech
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Gamida Cell
Tags search
HOME
24/7
buzz
STARTUPS
VC
Tech@work
Innovation
OPINIONS
EVENTS
ABOUT
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
20:16
Full list of Israeli high-tech layoffs in 2022-23
18:53
Microsoft Israel to lay off dozens as part of global cutbacks
14:30
CyberArk founder: "The process of building a high-tech company is full of endless failures"
14:18
Deloitte Launchpad announces 5th cohort with 10 new startups
More stories
Buzz
Most popular
Daily
Weekly
1
Deloitte Launchpad announces 5th cohort with 10 new startups
2
Creator investment platform Exceed raises $8 million Seed round
3
"Investments in Israel have all but disappeared - also because of the judicial coup”
4
The 50 most promising Israeli startups - 2022
5
daily.dev raises $11 million in Seed funding to build a professional network for developers
More news
Gamida Cell
5 stories about Gamida Cell
Gamida Cell announces $75 million financing with Highbridge Capital Management
16.02.21
|
CTech
The Israeli company is developing and commercializing cures for blood cancers and serious hematologic diseases
Gamida Cell Downprices Shares to Raise $50 Million Nasdaq IPO
28.10.18
|
Lilach Baumer
The Israel-based biotech company offered its shares at $8, below its previous intention of $13 to $15 per share
Novartis-Backed Gamida Downgrades Nasdaq IPO Expectations to $50-$60 Million
18.10.18
|
Lilach Baumer
The Jerusalem-based biotech company filed for a $69 million initial public offering in September but disclosed no pricing terms
Biotech Company Gamida Cell Files for $69 Million Nasdaq IPO
30.09.18
|
Dror Reich
The Jerusalem-based company develops cellular and immune therapies. Its lead product is a universal bone marrow transplant solution
Pharma Veteran Julian Adams takes Helm at Gamida Cell
21.11.17
|
Lilach Baumer
The Novartis-backed company is developing a universal bone marrow transplant solution for patients unable to find a donor
Please ensure Javascript is enabled for purposes of
website accessibility